Jaguar Health, Inc. (NASDAQ:JAGX) | WebDisclosure

Switch to English

10374	Sociétés
216189	Mots-clés
145888	Articles
114464	Communiqués

Accueil
Sociétés
Jaguar Health, Inc.

COMMUNIQUÉ DE PRESSE

publié le 23/06/2025 à 15:00, il y a 10 mois 17 jours

Jaguar Health Provides Updates on Orphan Disease Intestinal Failure Development Program for Crofelemer
Enrollment in Jaguar Health's placebo-controlled Phase 2 study for microvillus inclusion disease (MVID) reaches 25%. Crofelemer shows promise in reducing total parenteral nutrition in pediatric patients with MVID and short bowel syndrome, seeking business partnerships for non-dilutive funding

Crofelemer Jaguar Health Phase 2 Study MVID Intestinal Failure
BRÈVE

publiée le 17/06/2025 à 15:05, il y a 10 mois 23 jours

Jaguar Health participera à la conférence Emerging Growth

Napo Pharmaceuticals Crofelemer Jaguar Health Lisa Conte Conférence Sur La Croissance Émergente
BRÈVE

publiée le 17/06/2025 à 15:05, il y a 10 mois 23 jours

Jaguar Health to Present at Emerging Growth Conference

Napo Pharmaceuticals Crofelemer Jaguar Health Lisa Conte Emerging Growth Conference
COMMUNIQUÉ DE PRESSE

publié le 17/06/2025 à 15:00, il y a 10 mois 23 jours

Jaguar Health Presenting June 18 at Emerging Growth Conference to Provide Updates on Near-Term Catalysts
Jaguar Health, Inc. to present virtually at Emerging Growth Conference on June 18, 2025. Focus on pharmaceuticals from rainforest plants for gastrointestinal distress. Notable brands: Mytesi, Napo Therapeutics

Pharmaceuticals Gastrointestinal Distress Jaguar Health Emerging Growth Conference Mytesi
BRÈVE

publiée le 11/06/2025 à 16:05, il y a 10 mois 29 jours

Jaguar Health lance une étude sur le médicament Canalevia-CA1 chez le chien

Crofelemer Jaguar Health Canalevia-CA1 Approbation De La FDA Diarrhée Du Chien
BRÈVE

publiée le 11/06/2025 à 16:05, il y a 10 mois 29 jours

Jaguar Health Launches Study for Canalevia-CA1 Drug in Dogs

Crofelemer FDA Approval Jaguar Health Canalevia-CA1 Dog Diarrhea
COMMUNIQUÉ DE PRESSE

publié le 11/06/2025 à 16:00, il y a 10 mois 29 jours

First Study Site Established for Jaguar Health Study of its FDA Conditionally Approved Canalevia-CA1 Prescription Drug for Dogs
Jaguar Health, Inc. announces goals to expand crofelemer usage from chemotherapy-induced to general diarrhea treatment in dogs. Research studies and partnerships in progress

Crofelemer Jaguar Health Partnerships Dogs Diarrhea Treatment
BRÈVE

publiée le 09/06/2025 à 22:20, il y a 11 mois

Jaguar Health discutera des résultats de l'essai de phase 3 lors d'une discussion virtuelle

Jaguar Health Essai De Phase 3 Cancer Du Sein Maladies Orphelines Réunion De La FDA
BRÈVE

publiée le 09/06/2025 à 22:20, il y a 11 mois

Jaguar Health to Discuss Phase 3 Trial Results in Virtual Chat

Jaguar Health Phase 3 Trial Breast Cancer Orphan Diseases FDA Meeting
COMMUNIQUÉ DE PRESSE

publié le 09/06/2025 à 22:15, il y a 11 mois

REMINDER: Jaguar Health to Conduct Fireside Chat 9AM ET June 10 as Part of Lytham Partners’ Spring 2025 Spotlight Series
Jaguar Health, Inc. to discuss Phase 3 OnTarget trial results for metastatic breast cancer subgroup. Focus on orphan population and expanded access program. Virtual fireside chat with CEO Lisa Conte on June 10, 2025

Jaguar Health Phase 3 OnTarget Trial Virtual Fireside Chat Metastatic Breast Cancer Orphan Population

Les Echos

Publié le 07/05/2026 à 19:15, il y a 3 jours 2 heures

2026 Annual General Meeting: approval of all resolutions submitted to the Meeting
Publié le 07/05/2026 à 19:15, il y a 3 jours 2 heures

Assemblée Générale annuelle 2026 : approbation de l’ensemble des résolutions soumises au vote
Publié le 07/05/2026 à 19:06, il y a 3 jours 3 heures

Disclosure of Share Capital and Voting Rights as of April 30, 2026
Publié le 07/05/2026 à 19:06, il y a 3 jours 3 heures

Déclaration du nombre d’actions et droits de vote au 30 avril 2026
Publié le 07/05/2026 à 19:00, il y a 3 jours 3 heures

ALTAREIT - INFORMATION RELATIVE AU NOMBRE TOTAL DE DROITS DE VOTE ET D’ACTIONS COMPOSANT LE CAPITAL SOCIAL

Voir tout LES ECHOS COMFI WIRE

Accesswire

Publié le 09/05/2026 à 01:55, il y a 1 jour 20 heures

Prospect Ridge Announces Board Resignation
Publié le 09/05/2026 à 01:40, il y a 1 jour 20 heures

Findev Inc. Issues Corrective Disclosure
Publié le 09/05/2026 à 01:30, il y a 1 jour 20 heures

Star Copper Announces Agreement with Zimtu Capital Corp.
Publié le 09/05/2026 à 00:00, il y a 1 jour 22 heures

Onco-Innovations Progresses Toward IND Preparation as Nucro-Technics Commences Bioanalysis for PNKP Inhibitor Technology
Publié le 08/05/2026 à 23:01, il y a 1 jour 23 heures

Water Ways Announces Corporate Updates

Voir tout ACCESSWIRE

EQS Group

Publié le 10/05/2026 à 16:05, il y a 6 heures 1 minute

RingConn Gen 3 Smart Ring Opens for Pre-Order: Bringing Vascular Insights to Effortless Everyday Wear
Publié le 10/05/2026 à 14:00, il y a 8 heures 6 minutes

MBC GROUP DELIVERS RESILIENT 1Q 2026 PERFORMANCE ANCHORED BY STRONG MBC SHAHID GROWTH
Publié le 10/05/2026 à 11:45, il y a 10 heures 21 minutes

Hisense Kicks Off FIFA World Cup 2026™ Campaign, Bringing Fans Closer Through "Innovating a Brighter Life"
Publié le 09/05/2026 à 19:05, il y a 1 jour 3 heures

LONGi EcoLife Series Module Top TaiyangNews Global Ranking, Ushering in the "25%+" Era of Photovoltaic Efficiency
Publié le 08/05/2026 à 20:38, il y a 2 jours 1 heure

EQS-Adhoc: thyssenkrupp nucera AG & Co. KGaA: Preliminary Figures for Q2/6M 2025/26; Order Intake Above Expectations and Previous Year ; Sales and Earnings below Market Expectations